Sanofi India has launched its’ new diabetes drug Soliqua after having received the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year. Soliqua is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
Soliqua is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist. This is now accessible at a nominal therapy cost of Rs 1850 per pen, enabling wider access to patients living with type 2 diabetes mellitus.
Soliqua is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist. This is now accessible at a nominal therapy cost of Rs 1850 per pen, enabling wider access to patients living with type 2 diabetes mellitus.
The post appeared first on .